Literature DB >> 6243721

Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics.

I T Magrath, P A Pizzo, J Whang-Peng, E C Douglass, O Alabaster, P Gerber, C B Freeman, L Novikovs.   

Abstract

Sixteen lymphoid cell lines were derived from patients with undifferentiated lymphoma of Burkitt's or non-Burkitt's type. They were obtained directly from tumor biopsies, from serous effusions, or from bone marrow. In 10 of the cell lines, the Epstein-Barr virus (EBV) nuclear antigen (EBNA) was undetectable; the remaining 6 lines were EBNA-positive (EB-pos). Of the 16 lines, 15 were aneuploid, with detectable chromosome "14q+ markers (11 had +8;14 translocations). These 15 lines, which included the EBNA-negative (EB-neg) lines, were believed to be of tumor cell origin. The remaining line consisted predominantly of diploid cells derived from normal lymphocytes, but some cells of tumor origin were present. Four EB-pos cell lines derived from EB-neg tumors had an aneuploid karyotype consistent with an origin from tumor cells (including no.8;14 translocation in two), which suggested that either tumor cells were infected with EBV in vitro or a tiny fraction of EB-pos tumor cells (or potential tumor cells) present in vivo gave rise to the predominant cell of the line. EB-neg B-cell lines and EB-pos cell lines established from undifferentiated lymphomas differed greatly. EB-neg lines had consistently smaller electronic mean cell volumes and narrow-angle light scatter than did EB-pos lines. This finding correlated with a lower nuclear:cytoplasmic ratio in EB-pos lines. EB-neg lines also had higher saturation cell densities than did EB-pos lines under standard culture conditions. The data indicate either that EBV influences the morphologic and physiologic characteristics of lymphoid cell lines or that EB-neg B-cell lines and EB-pos cell lines are derived ultimately from different lymphocyte subpopulations or that both may apply.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243721

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.

Authors:  Elaine J Schattner; Steven M Friedman; Paolo Casali
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

2.  Efficient infection of a human B cell line with cell-free Kaposi's sarcoma-associated herpesvirus.

Authors:  Stephen J Dollery; Rey J Santiago-Crespo; Lela Kardava; Susan Moir; Edward A Berger
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

3.  Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infections.

Authors:  I Kurane; U Kontny; J Janus; F A Ennis
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  Expression of cellular myc and mos genes in undifferentiated B cell lymphomas of Burkitt and non-Burkitt types.

Authors:  R T Maguire; T S Robins; S S Thorgeirsson; C A Heilman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

5.  The t(8;14) breakpoint of the EW 36 undifferentiated lymphoma cell line lies 5' of MYC in a region prone to involvement in endemic Burkitt's lymphomas.

Authors:  F G Haluska; Y Tsujimoto; C M Croce
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

6.  Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells.

Authors:  T Ishiji; M J Lace; S Parkkinen; R D Anderson; T H Haugen; T P Cripe; J H Xiao; I Davidson; P Chambon; L P Turek
Journal:  EMBO J       Date:  1992-06       Impact factor: 11.598

7.  No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines.

Authors:  K J Williams; J Heighway; J M Birch; J D Norton; D Scott
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.